Relmada Therapeutics, Inc. (RLMD)

Relmada Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	1.15	3.86	4.09	5.4	44.44	2.5
Short-Term Investments	25.91	41.05	92.23	142.93	167.47	114.6
Cash & Short-Term Investments	27.06	44.91	96.32	148.32	211.91	117.09
Cash Growth	-67.64%	-53.38%	-35.06%	-30.01%	80.98%	0.56%
Other Receivables	-	-	-	0.51	0.09	0.08
Receivables	-	-	-	0.51	0.09	0.08
Prepaid Expenses	0.6	0.89	1.19	4.04	11.3	0.9
Total Current Assets	27.66	45.8	97.51	152.87	223.3	118.07
Property, Plant & Equipment	-	-	-	-	-	0
Other Long-Term Assets	0.02	0.02	0.04	0.03	0.03	0.11
Total Assets	27.68	45.82	97.55	152.91	223.33	118.19
Accounts Payable	1.27	4.13	3.51	5.26	11.19	8.35
Accrued Expenses	3.97	6.16	8.69	7.21	3.87	4.26
Total Current Liabilities	5.23	10.29	12.19	12.47	15.06	12.6
Other Long-Term Liabilities	0.01	0	-	-	-	-
Total Liabilities	5.24	10.3	12.19	12.47	15.06	12.6
Common Stock	0.03	0.03	0.03	0.03	0.03	0.02
Additional Paid-In Capital	680.85	676.37	646.23	602.52	513.3	284.88
Retained Earnings	-658.44	-640.88	-560.9	-462.11	-305.07	-179.32
Total Common Equity	22.44	35.52	85.36	140.44	208.26	105.58
Shareholders' Equity	22.44	35.52	85.36	140.44	208.26	105.58
Total Liabilities & Equity	27.68	45.82	97.55	152.91	223.33	118.19
Net Cash (Debt)	27.06	44.91	96.32	148.32	211.91	117.09
Net Cash Growth	-67.64%	-53.38%	-35.06%	-30.01%	80.98%	0.65%
Net Cash Per Share	0.90	1.49	3.20	5.01	12.07	7.51
Filing Date Shares Outstanding	33.19	33.19	30.17	30.1	29.37	16.75
Total Common Shares Outstanding	33.19	30.1	30.1	30.1	27.74	16.33
Working Capital	22.43	35.5	85.31	140.4	208.24	105.47
Book Value Per Share	0.68	1.18	2.84	4.67	7.51	6.46
Tangible Book Value	22.44	35.52	85.36	140.44	208.26	105.58
Tangible Book Value Per Share	0.68	1.18	2.84	4.67	7.51	6.46

Updated Mar 27, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q